We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.23B
AUM Growth
-$138M
Cap. Flow
+$87.1M
Cap. Flow %
7.07%
Top 10 Hldgs %
28.99%
Holding
134
New
17
Increased
54
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$37.8M
2
AET
Aetna Inc
AET
+$26.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$23.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$21.1M
5
CHMA
Chiasma, Inc. Common Stock
CHMA
+$13M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$42.2M
2
HUM icon
Humana
HUM
+$25.2M
3
THOR
THORATEC CORPORATION
THOR
+$24.5M
4
BHC icon
Bausch Health
BHC
+$17.9M
5
MCK icon
McKesson
MCK
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 76.04%
2 Financials 3.43%
3 Technology 0.48%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
101
DELISTED
Orexigen Therapeutics, Inc.
OREX
$3.48M 0.28%
165,000
+10,000
+6% +$343K
ADXS
102
DELISTED
Advaxis Inc
ADXS
$3.45M 0.28%
22,467
-5,366
-19% -$1.3M
SCYX icon
103
SCYNEXIS
SCYX
$52M
$3.42M 0.28%
5,875
+3,675
+167% +$2.25M
NBRV
104
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.08M 0.25%
+1,298
New +$3.44M
CGEN icon
105
Compugen
CGEN
$228M
$2.71M 0.22%
+525,000
New +$3.06M
GBT
106
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.53M 0.21%
+60,000
New +$2.83M
ANTH
107
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.44M 0.2%
50,000
-8,750
-15% -$611K
DARE icon
108
Dare Bioscience
DARE
$21M
$2.29M 0.19%
5,208
– –
DYAX
109
DELISTED
DYAX CORPORATION
DYAX
$2.19M 0.18%
114,500
+12,000
+12% +$287K
XNPT
110
DELISTED
XENOPORT, INC.
XNPT
$1.93M 0.16%
555,000
+230,000
+71% +$1.45M
ONCE
111
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.91M 0.15%
+45,700
New +$2.38M
FPRX
112
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.85M 0.15%
120,000
– –
RPTP
113
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$1.84M 0.15%
305,000
– –
INFI
114
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.82M 0.15%
215,000
– –
ALBO
115
DELISTED
Albireo Pharma Inc
ALBO
$1.76M 0.14%
133,333
– –
CNXR
116
DELISTED
Connecture, Inc.
CNXR
$1.66M 0.14%
365,000
-260,000
-42% -$2.06M
KIN
117
DELISTED
Kindred Biosciences, Inc.
KIN
$1.43M 0.12%
275,000
– –
PBYI icon
118
Puma Biotechnology
PBYI
$454M
$1.2M 0.1%
15,900
+4,900
+45% +$463K
PTCT icon
119
PTC Therapeutics
PTCT
$6.12B
$1.15M 0.09%
42,960
-40
-0.1% -$1.71K
DBVT
120
DBV Technologies
DBVT
$847M
$890K 0.07%
+2,500
New +$983K
ROKA
121
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$485K 0.04%
25,000
– –
AVDL
122
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-75,000
Closed -$1.59M
DHR icon
123
Danaher
DHR
$144B
– –
-156,966
Closed -$9.03M
HUM icon
124
Humana
HUM
$46.2B
– –
-131,500
Closed -$25.2M
ILMN icon
125
Illumina
ILMN
$28.4B
– –
-18,247
Closed -$3.88M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rock Springs Capital Management held 134 positions worth $1.23B, down 10% from $1.37B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $87.1M of net new capital in Q3 2015, opening 17 new positions and adding to 54 existing holdings. Its largest new stake was St Jude Medical: 530,000 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $24.5M trimmed.

  • Rock Springs Capital Management's largest Q3 2015 buy was St Jude Medical: 530,000 shares worth $33.4M.
  • Rock Springs Capital Management added most to Aetna Inc in Q3 2015, an estimated $26.5M increase.
  • Rock Springs Capital Management's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $24.5M.
  • Rock Springs Capital Management fully exited Medtronic in Q3 2015, selling an estimated $42.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.23B portfolio in Q3 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 13 in Q3 2015.
  • Rock Springs Capital Management's portfolio value fell 10% quarter-over-quarter to $1.23B.

Based on Rock Springs Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.